Mr. Chris Dallin reports

ASEP MEDICAL ANNOUNCES LIFE FINANCING

ASEP Medical Holdings Inc. intends to complete a non-brokered private placement financing under the listed issuer financing exemption (LIFE) for maximum gross proceeds of $900,000.

The LIFE offering will consist of a maximum of nine million units of the company at a price of 10 cents per unit. Each unit will consist of one common share in the capital of the company and one common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share at an exercise price of 12 cents per common share for a period of 24 months following closing.

The company intends to use the available funds from the LIFE offering, together with its existing additional sources of financing, primarily for the identification and evaluation of companies and technologies for potential acquisition and integration into the company's business, repayment of existing debts and general working capital purposes.

The LIFE offering is expected to close on or about Oct. 30, 2026, or such other date or dates as the company may determine and may close in one or more tranches. The LIFE offering is subject to the approval of the Canadian Securities Exchange. The company has not engaged any dealers or finders in connection with the LIFE offering, and no commissions, finders' fees or finder warrants will be paid or issued in connection with the LIFE offering.

The LIFE offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106, Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935, Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, and is being made to purchasers resident in all provinces of Canada, other than Quebec. The securities issued pursuant to the LIFE offering are expected to be immediately freely tradable under applicable Canadian securities legislation.

There is an offering document related to the LIFE offering that can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read this offering document before making an investment decision.

About ASEP Medical Holdings Inc.

ASEP Medical is an investment issuer focused on investing into biotechnology research and development assets and is based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E.W. Hancock, one of the world's foremost microbiologists. ASEP holds a significant interest in two private companies -- Sepset Biosciences (ASEP's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

We seek Safe Harbor.